Integra Lifesciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Integra Lifesciences (IART).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

3S.Buy

1Buy

6Hold

3Sell

Consensus RatingMarket Outperform# Analysts13Avg. Consensus PT$21Upside to Avg. PT+75.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 22, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$15→$14
Oct 22, 2026	BMO Capital	Vik Chopra	PT Cut	Market Perform	$15→$14
Oct 22, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$15→$13
Oct 22, 2026	Citizens	Daniel Stauder	PT Cut	Market Outperform	$25→$22
Oct 22, 2026	JP Morgan	Robbie Marcus	PT Cut	Underweight	$17→$14
Oct 14, 2026	Truist Securities	Ravi Misra	PT Cut	Hold	$19→$15
Oct 5, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$19→$15
Oct 5, 2026	BMO Capital	Vik Chopra	PT Cut	Market Perform	$18→$15
Jul 30, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$15→$18
Jul 28, 2026	UBS	Patrick Wood	Initiate	Neutral	$19
Jul 16, 2026	Truist Securities	Ravi Misra	PT Raise	Hold	$14→$19
Jul 9, 2026	BMO Capital	Vik Chopra	Initiate	Market Perform	$19
Jul 8, 2026	Citigroup	Joanne Wuensch	PT Raise	Neutral	$16→$19
May 28, 2026	Citigroup	Joanne Wuensch	Upgrade	Sell→Neutral	$11→$16
May 6, 2026	Citigroup	Joanne Wuensch	PT Raise	Sell	$9→$11
May 6, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$12→$15
Apr 15, 2026	Truist Securities	Ravi Misra	PT Cut	Hold	$13→$12
Apr 15, 2026	Argus Research	David Toung	Downgrade	Buy→Hold	—
Mar 11, 2026	Citigroup	Joanne Wuensch	PT Cut	Sell	$11→$9
Feb 27, 2026	Wells Fargo	Vik Chopra	PT Cut	Equal-Weight	$13→$12

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.

Benzinga Newsdesk

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22

Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.

Benzinga Newsdesk

PRO
JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14

JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $19 to $15.

Benzinga Newsdesk

Integra Lifesciences Holdings Corp

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Integra Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

PRO
Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22

PRO
JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

People Also Watch

People Also Watch

Integra Lifesciences Holdings Corp

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Integra Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

PROBMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

PROWells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

PROCitizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22

PROJP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14

PROTruist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

People Also Watch

People Also Watch

PRO
Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

PRO
Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22

PRO
JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15